Truist Financial Issues Positive Forecast for Pediatrix Medical Group (NYSE:MD) Stock Price

Pediatrix Medical Group (NYSE:MD) had its price target hoisted by Truist Financial from $13.00 to $16.00 in a research report report published on Monday, Benzinga reports. Truist Financial currently has a hold rating on the stock.

MD has been the subject of a number of other research reports. Jefferies Financial Group upgraded Pediatrix Medical Group from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $8.00 to $14.00 in a research report on Thursday, September 26th. StockNews.com upgraded shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research report on Wednesday, August 7th. UBS Group boosted their price target on Pediatrix Medical Group from $9.00 to $10.50 and gave the company a “neutral” rating in a report on Friday, August 9th. Finally, Mizuho raised their price objective on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Monday. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $14.90.

Pediatrix Medical Group Price Performance

Pediatrix Medical Group stock traded up $0.17 during mid-day trading on Monday, reaching $15.31. The company had a trading volume of 26,233 shares, compared to its average volume of 868,968. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.58 and a quick ratio of 1.38. The company has a market capitalization of $1.31 billion, a P/E ratio of -4.95, a P/E/G ratio of 2.36 and a beta of 1.55. Pediatrix Medical Group has a 1 year low of $6.62 and a 1 year high of $15.43. The stock’s 50-day simple moving average is $11.70 and its 200-day simple moving average is $9.45.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.07. The company had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.29 earnings per share. On average, equities analysts predict that Pediatrix Medical Group will post 1.19 EPS for the current year.

Insider Transactions at Pediatrix Medical Group

In other news, CFO C Marc Richards sold 32,562 shares of the business’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $10.08, for a total transaction of $328,224.96. Following the completion of the sale, the chief financial officer now owns 192,785 shares in the company, valued at approximately $1,943,272.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Pediatrix Medical Group news, CEO James D. Swift sold 11,100 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the transaction, the chief executive officer now directly owns 170,001 shares of the company’s stock, valued at $1,834,310.79. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO C Marc Richards sold 32,562 shares of the company’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $10.08, for a total transaction of $328,224.96. Following the completion of the sale, the chief financial officer now directly owns 192,785 shares in the company, valued at $1,943,272.80. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 68,100 shares of company stock worth $701,889 in the last ninety days. Insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Pediatrix Medical Group

Large investors have recently modified their holdings of the stock. Aristeia Capital L.L.C. bought a new stake in Pediatrix Medical Group during the second quarter valued at $687,000. Vanguard Group Inc. boosted its stake in Pediatrix Medical Group by 1.6% in the first quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock valued at $105,892,000 after acquiring an additional 164,333 shares during the period. Boston Partners lifted its holdings in shares of Pediatrix Medical Group by 34.0% in the 1st quarter. Boston Partners now owns 1,786,434 shares of the company’s stock worth $17,702,000 after purchasing an additional 453,254 shares during the last quarter. Rubric Capital Management LP grew its position in shares of Pediatrix Medical Group by 797.0% during the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after acquiring an additional 7,241,400 shares during the last quarter. Finally, ClariVest Asset Management LLC bought a new stake in shares of Pediatrix Medical Group during the second quarter valued at approximately $1,721,000. Institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.